Theriva Biologics
TOVX
33 hedge funds and large institutions have $3.24M invested in Theriva Biologics in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 6 closing their positions.
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
0.01% more ownership
Funds ownership: 0.02% → 0.04% (+0.01%)
3% less capital invested
Capital invested by funds: $3.32M → $3.24M (-$86K)
3% less funds holding
Funds holding: 34 → 33 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.22M |
| 2 |
Truist Financial
Charlotte,
North Carolina
|
+$415K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$88.4K |
| 4 |
MP
MSD Partners
New York
|
+$87.8K |
| 5 |
VF
Virtu Financial
New York
|
+$52.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$126K |
| 2 |
Two Sigma Investments
New York
|
-$48.7K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$10K |
| 4 |
CWA
Clearview Wealth Advisors
Salem,
Oregon
|
-$9K |
| 5 |
Mercer Global Advisors
Denver,
Colorado
|
-$9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $3K | +$3.68K | +39 | +3,900% |
|
27
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $3 | -$4.9K | -52 | -55% |
|
|
GCP
28
GSA Capital Partners
London,
United Kingdom
| – | -$126K | -1,101 | Closed |
|
|
29
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$10K | -88 | Closed |
|
|
CWA
30
Clearview Wealth Advisors
Salem,
Oregon
| – | -$9K | -82 | Closed |
|
|
31
Mercer Global Advisors
Denver,
Colorado
| – | -$9K | -80 | Closed |
|
|
HF
32
HRT Financial
New York
| – | -$6K | -55 | Closed |
|
|
SWP
33
Stratos Wealth Partners
Beachwood,
Ohio
| – | -$5K | -40 | Closed |
|
34
Bank of America
Charlotte,
North Carolina
| – | -$189 | -2 | -67% |
|
|
LFG
35
Leverty Financial Group
Hudson,
Wisconsin
| – | +$94 | +1 | New |
|
TOVX Hedge Fund Activity: Q4 2021 in Review
33 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q4 2021, worth a combined $3.24M — down 2.6% from $3.32M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TOVX and 5 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 11 added.
The largest buyer was Vanguard Group, adding an estimated $1.22M. The largest seller was GSA Capital Partners, exiting entirely with an estimated $126K sold.
- 33 institutional investors held Theriva Biologics (TOVX) as of Q4 2021, down from 34 in Q3 2021.
- Funds reported $3.24M of Theriva Biologics stock for Q4 2021, down 2.6% quarter-over-quarter.
- 5 funds opened new Theriva Biologics positions in Q4 2021 and 6 closed out, a net change of -1 holder.
- The largest Theriva Biologics buyer in Q4 2021 was Vanguard Group, an estimated $1.22M added.
- The largest Theriva Biologics seller in Q4 2021 was GSA Capital Partners, an estimated $126K sold.
Based on aggregated 13F filings for Q4 2021.